Ascendis Pharma A/S

Common Name

Ascendis Pharma

Country

Denmark

Sector

Healthcare

Industry

Biotechnology

Employees

1,017

Ticker

ASND

Exchange

NASDAQ/NGS

Website

ascendispharma.dk

Description

Ascendis Pharma A/S is a biopharmaceutical company that focuses on developing innovative drug therapies for unmet medical needs. The company employs its proprietary TransCon technology platform to cre... Show more

Financial Statements of Ascendis Pharma

Below are the financial statements of Ascendis Pharma, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.

Income Statement (as reported) Balance Sheet (as reported)

All figures in millions of EUR	2024	2023
Non-current assets	—	—
Intangible assets	4.03^a	4.42^a
Intangible assets	0	4.83^a
Property, plant and equipment	98.71^a	110.63^a
Property, plant and equipment	0	129.1^a
Investments in associates	13.58^a	5.69^a
Investments in associates	0	22.93^a
Other receivables	2.32^a	2.13^a
Other receivables	0	1.92^a
Marketable securities	0^a	0^a
Marketable securities	0	7.49^a
Non-current assets	118.63^a	122.87^a
Non-current assets	0	166.27^a
Current assets	—	—
Inventories	295.61^a	208.93^a
Inventories	0	130.67^a
Trade receivables	166.28^a	35.87^a
Trade receivables	0	11.91^a
Income tax receivables	1.78^a	0.8^a
Income tax receivables	0	0.88^a
Other receivables	9.39^a	19.1^a
Other receivables	0	12.83^a
Prepayments	28.27^a	38.58^a
Prepayments	0	31.72^a
Marketable securities	0^a	7.28^a
Marketable securities	0	290.69^a
Cash and cash equivalents	559.54^a	392.16^a
Cash and cash equivalents	0	444.77^a
Current assets	1,060.86^a	702.72^a
Current assets	0	923.47^a
Total assets	1,179.5^a	825.59^a
Total assets	0	1,089.74^a
Equity	—	—
Share capital	8.15^a	7.75^a
Share capital	0	7.68^a
Distributable equity	-113.86^a	-153.45^a
Distributable equity	0	255.67^a
Total equity	-105.71^a	-145.7^a
Total equity	0	263.35^a
Non-current liabilities	—	—
Borrowings	365.08^a	223^a
Borrowings	0	95.4^a
Contract liabilities	5^a	5.95^a
Contract liabilities	0	14.21^a
Deferred tax liabilities	7.26^a	5.83^a
Deferred tax liabilities	0	0^a
Non-current liabilities	377.34^a	234.78^a
Non-current liabilities	0	109.61^a
Current liabilities	—	—
Convertible notes, matures in April 2028 borrowings	458.21^a	407.1^a
Convertible notes, matures in April 2028 borrowings	0	399.19^a
Derivative liabilities	150.67^a	143.3^a
Derivative liabilities	0	157.95^a
Other current liabilities	—	—
Borrowings	33.33^a	14.17^a
Borrowings	0	13.79^a
Contract liabilities	0.94^a	1.18^a
Contract liabilities	0	0^a
Trade payables and accrued expenses	96.39^a	94.57^a
Trade payables and accrued expenses	0	101.03^a
Other liabilities	67.96^a	41.18^a
Other liabilities	0	31.99^a
Income tax payables	1.22^a	2.3^a
Income tax payables	0	5.49^a
Provisions	99.15^a	32.72^a
Provisions	0	7.34^a
Other current liabilities	298.99^a	186.12^a
Other current liabilities	0	159.64^a
Current liabilities	907.86^a	736.51^a
Current liabilities	0	716.78^a
Total liabilities	1,285.2^a	971.28^a
Total liabilities	0	826.39^a
Total equity and liabilities	1,179.5^a	825.59^a
Total equity and liabilities	0	1,089.74^a

Verified Sources Behind Ascendis Pharma’s Financial Fundamentals Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Ascendis Pharma’s data sources below and access millions more through our Disclosure Search.

a. Ascendis Pharma's Annual Report 2024

Trace every data point back to Ascendis Pharma’s disclosures

Sign up for Tracenable and access millions of corporate disclosures, including annual reports and sustainability filings from global companies, completely free of charge.

Real-Time & Standardized Financials

Access Standardized Financial Statements within Minutes of Disclosure

At Tracenable, we're exploring the launch of real-time standardized financial datafeeds and APIs covering global equities. Unlike limited and inconsistent XBRL parsing, our approach aims to deliver clean, comparable, and fully traceable data seconds after publication.

Could this solution support your investment or analytical workflows?

Explore Peer Companies

Welcome Back to Tracenable

Sign in to your account

Ascendis Pharma A/S

Financial Statements of Ascendis Pharma

Verified Sources Behind Ascendis Pharma’s Financial Fundamentals Data

Access Standardized Financial Statements within Minutes of Disclosure

Explore Peer Companies

Genmab A/S

GN Store Nord A/S

H Lundbeck A/S

Ambu A/S

Demant A/S

Novo Nordisk A/S